Last reviewed · How we verify
Dasabuvir mini tablet
NS5A replication complex inhibitor
NS5A replication complex inhibitor Used for Chronic hepatitis C.
At a glance
| Generic name | Dasabuvir mini tablet |
|---|---|
| Also known as | Exviera, ABT-333 |
| Sponsor | AbbVie |
| Drug class | NS5A inhibitor |
| Target | NS5A |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Dasabuvir is a non-nucleoside inhibitor of the NS5A protein of the hepatitis C virus, which is essential for viral replication.
Approved indications
- Chronic hepatitis C
Common side effects
- Fatigue
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dasabuvir mini tablet CI brief — competitive landscape report
- Dasabuvir mini tablet updates RSS · CI watch RSS
- AbbVie portfolio CI